Thermo Fisher Scientific Inc. $TMO Stock: Rathbones Group PLC Reduces Holdings

Rathbones Group PLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 8.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 917,269 shares of the medical research company’s stock after selling 88,191 shares during the quarter. Thermo Fisher Scientific makes up about 2.2% of Rathbones Group PLC’s portfolio, making the stock its 9th largest holding. Rathbones Group PLC’s holdings in Thermo Fisher Scientific were worth $619,202,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of TMO. BlackRock Inc. acquired a new position in Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $1,974,561,000. Bank of America Corp DE acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $1,952,930,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after acquiring an additional 22,827 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $1,122,351,000. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the sale, the vice president directly owned 11,560 shares of the company’s stock, valued at $8,166,562. This trade represents a 19.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.33% of the company’s stock.

Key Stories Impacting Thermo Fisher Scientific

These are some of the TMO stories that stood out recently:

Thermo Fisher Scientific Trading Down 2.9%

NYSE:TMO opened at $668.89 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $727.56. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $247.84 billion, a price-to-earnings ratio of 35.28, a PEG ratio of 2.82 and a beta of 0.84. The firm has a fifty day simple moving average of $678.63 and a two-hundred day simple moving average of $559.30.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.79 earnings per share. Analysts expect that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.92%.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Guggenheim started coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They set a “buy” rating and a $740.00 target price on the stock. Argus raised their target price on Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. TD Cowen lifted their target price on Thermo Fisher Scientific from $760.00 to $810.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $690.00 to $760.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Finally, The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $650.00 to $780.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $683.64.

View Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.